TN2010000568A1 - Pegylated insulin lispro compounds - Google Patents
Pegylated insulin lispro compoundsInfo
- Publication number
- TN2010000568A1 TN2010000568A1 TNP2010000568A TN2010000568A TN2010000568A1 TN 2010000568 A1 TN2010000568 A1 TN 2010000568A1 TN P2010000568 A TNP2010000568 A TN P2010000568A TN 2010000568 A TN2010000568 A TN 2010000568A TN 2010000568 A1 TN2010000568 A1 TN 2010000568A1
- Authority
- TN
- Tunisia
- Prior art keywords
- insulin lispro
- relates
- pegylated insulin
- lispro compounds
- pegylated
- Prior art date
Links
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical class C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 title abstract 2
- 108700002854 polyethylene glycol(B1)- insulin Proteins 0.000 title abstract 2
- -1 poly(ethylene glycol) Polymers 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2009/046704 WO2009152128A1 (en) | 2008-06-13 | 2009-06-09 | Pegylated insulin lispro compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2010000568A1 true TN2010000568A1 (en) | 2012-05-24 |
Family
ID=55024647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2010000568A TN2010000568A1 (en) | 2009-06-09 | 2010-12-10 | Pegylated insulin lispro compounds |
Country Status (1)
| Country | Link |
|---|---|
| TN (1) | TN2010000568A1 (en) |
-
2010
- 2010-12-10 TN TNP2010000568A patent/TN2010000568A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY158890A (en) | Pegylated insulin lispro compounds | |
| UA101497C2 (en) | Conjugates of factor ix with increased half-life | |
| WO2009109927A3 (en) | Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer | |
| MX342423B (en) | 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients. | |
| PH12018500449A1 (en) | Polymeric bile acid nanocompositions targeting the pancreas and colon | |
| EP4253395A3 (en) | Processes for the preparation of carbohydrate conjugated rna agents | |
| WO2011008495A3 (en) | Arginase formulations and methods | |
| WO2011082270A3 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| MX2012013375A (en) | Pegylated c-peptide. | |
| WO2007100902A3 (en) | Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation | |
| WO2011082267A3 (en) | Substituted triazolo-pyrazine compounds | |
| EP2061456A4 (en) | Compositions and methods for inhibiting cytochrome p450 | |
| WO2011069037A3 (en) | Stabilization and storage of biological pharmaceutical compositions | |
| MX2012007225A (en) | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue. | |
| WO2011082268A3 (en) | Substituted naphthalenyl-pyrimidine compounds | |
| WO2009121997A3 (en) | Pegylated nanoparticles containing a biologically active molecule and use thereof | |
| EP2682129A3 (en) | Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous | |
| WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
| WO2008041116A3 (en) | Formulations of active principles incorporated in slns suitable for transdermal administration | |
| TN2010000568A1 (en) | Pegylated insulin lispro compounds | |
| UA101195C2 (en) | Pegylated insulin lispro compounds, pharmaceutical composition based thereon and method for producing thereof | |
| SG195192A1 (en) | Non-peptidyl polymer-insulin multimer and method for producing the same | |
| WO2009088831A3 (en) | Method of inhibiting abcg2 and other treatment methods | |
| WO2008005806A3 (en) | Therapeutic methods, compositions, and compounds | |
| WO2011087299A3 (en) | Pharmaceutical composition for the treatment of cancer, containing an extracellular matrix of mesenchymal stem cells derived from umbilical cord blood as an active ingredient |